Article in Japanese
An interim management strategy for rebound fever after intravenous immunoglobulin therapy for Kawasaki disease
Taishi NADA1), Atsuo SATO1), Rie TSUKUI1), Hiroyuki SHIRO1)
Refervescence after intravenous immunoglobulin (IVIG) therapy for Kawasaki disease, also called rebound fever, is sometimes clinically perplexing. To determine an interim management strategy for rebound fever, 178 patients diagnosed as having Kawasaki disease were evaluated retrospectively after receiving IVIG therapy and remaining afebrile for 24 hours and longer after the therapy. Among these patients, 34 (19%) had presented with rebound fever, which persisted for an average duration of 13 hours. The incidence of rebound fever was not associated with the types of IVIG preparation. Symptoms and laboratory findings at the time of diagnosis and completion of IVIG therapy showed no statistically significant differences between the rebound fever group and non-refervescence group. The rebound fever group had no coronary artery sequelae. These findings indicate that an interim management strategy for rebound fever could rule out infectious diseases and exacerbation of Kawasaki disease through symptom and laboratory analysis, followed by a wait-and-see approach for approximately 24 hours for suspected rebound fever.
1) Department of Pediatrics, Children's center, Yokohama Rosai Hospital
Key words | |
---|---|
Received | March 2, 2016 |
Accepted | June 1, 2016 |
28 (3):139─143,2016
- Vol. 36
- Vol. 35
- Vol. 34
- Vol. 33
- Vol. 32
- Vol. 31
- Vol. 30
- Vol. 29
- Vol. 28
- Vol. 27
- Vol. 26
- Vol. 25
- Vol. 24
- Vol. 23
- Vol. 22
- Vol. 21
- Vol. 20
- Vol. 19
- Vol. 18